CompletedNot Applicable

Prevalence of Thrombophilic Gene Polymorphism (MTHFR C677T) in COVID-19patients

Egypt46 participantsStarted 2022-05-11

Plain-language summary

Aim of the study is to find the prevalence of thrombophilic gene methylene tetrahydrofolate reductase (MTHFR) gene polymorphism in a sample of COVID-19 patients, aiming at early detection of MTHFR mutant patients and guiding preventive therapy.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * All adult patients diagnosed as COVID -19 by RT-PCR will be included Exclusion Criteria: * Patients younger than 18 years old Patients on Antithrombotic treatment before COVID-19.

What they're measuring

development of vascular thrombotic manifestation

Timeframe: 4 weeks

Trial details

NCT IDNCT05679414

SponsorAin Shams University

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2022-11-30

View on ClinicalTrials.gov More COVID 19 Associated Coagulopathy trials